OncoMatch/Clinical Trials/Neuroblastoma
Neuroblastoma Clinical Trials
OncoMatch filters Neuroblastoma trials by the molecular markers that determine eligibility — MYCN, ALK, PHOX2B, and more. Enter your biomarker results to see only the trials you may qualify for.
Compare eligibility criteriaAbout Neuroblastoma trials
Neuroblastoma is the most common extracranial solid tumor in children, arising from sympathetic nervous system precursors. MYCN amplification, present in 20-25% of cases, is a defining adverse prognostic feature and a primary axis of risk classification. ALK mutations (~10% somatic) and amplifications gate ALK inhibitor trials. PHOX2B mutations are germline in familial neuroblastoma and somatic in some sporadic cases, with implications for hereditary cancer screening in affected families.
Neuroblastoma trial activity organizes around risk classification and prior anti-GD2 therapy exposure. High-risk frontline trials (run primarily through the Children's Oncology Group) test intensification of the induction chemo / surgery / autologous stem cell transplant / radiation / immunotherapy backbone, with GD2-targeted antibodies now standard in high-risk consolidation. GD2-targeted CAR-T, bispecifics, and novel anti-GD2 ADCs are an active emerging space for relapsed disease. ALK-mutant trials test ALK inhibitors as monotherapy or in combinations. MYCN-driven trials test approaches targeting MYCN-related dependencies (BET inhibitors, Aurora kinase inhibitors). [131I]-MIBG (a radiolabeled targeted therapy) trials test combinations and earlier-line use. Familial neuroblastoma trials enroll patients with germline PHOX2B or ALK mutations for surveillance and prevention.
Common eligibility filters in neuroblastoma trials include risk classification, MYCN status, age, and prior anti-GD2 therapy. Risk classification by COG criteria (low, intermediate, high, ultra-high) determines treatment intensity and gates which trial set applies. MYCN amplification status by FISH is required for many high-risk trials. Prior anti-GD2 antibody exposure (which monoclonal and how many cycles) defines line for relapse trials. Prior autologous stem cell transplant status. Prior MIBG therapy exposure. ALK mutation testing for ALK inhibitor trials. Age varies by trial: most neuroblastoma trials are open to pediatric patients, with some adult relapse cases enrolled in age-expanded cohorts. Performance status using Lansky scale for younger patients or Karnofsky for older.
Top recruiting Neuroblastoma trials
Ranked by phase and number of US sites. See all trials matched to your profile →
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
National Cancer Institute (NCI)
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Children's Oncology Group
Induction Chemoimmunotherapy for Patients With High-risk Neuroblastoma
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
18F-DOPA II - PET Imaging Optimization
University of Alberta
Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)
St. Anna Kinderkrebsforschung
How OncoMatch finds Neuroblastoma trials for you
AI reads the protocol
Every Neuroblastoma trial on ClinicalTrials.gov has eligibility criteria written for regulators. OncoMatch uses large language models to extract the structured requirements — biomarkers, stage, prior therapy, and more — from that text.
You enter your results
Select Neuroblastoma and mark your biomarker results — MYCN, ALK, PHOX2B — as positive, negative, or not tested. Your data never leaves your device.
See only relevant trials
Results filter instantly. Each trial shows exactly which criteria you meet, which you don't, and which need more information. Bring the list to your oncologist.